IDEAYA Biosciences Closes $175.1M Public Offering
Ticker: IDYA · Form: 8-K · Filed: Oct 20, 2025 · CIK: 1676725
| Field | Detail |
|---|---|
| Company | Ideaya Biosciences, Inc. (IDYA) |
| Form Type | 8-K |
| Filed Date | Oct 20, 2025 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | bullish |
Sentiment: bullish
Topics: public-offering, financing, biotech
TL;DR
IDEAYA just closed a $175.1M stock offering at $17/share to fund pipeline development.
AI Summary
On October 17, 2025, IDEAYA Biosciences, Inc. announced the closing of its previously disclosed underwritten public offering. The company successfully sold approximately 10.3 million shares of common stock at a price of $17.00 per share, generating gross proceeds of about $175.1 million before deducting underwriting discounts and commissions. This offering is expected to provide IDEAYA with additional capital to advance its clinical programs and pipeline.
Why It Matters
The substantial capital raised will enable IDEAYA Biosciences to further develop its promising oncology drug candidates, potentially accelerating their path to market and benefiting patients.
Risk Assessment
Risk Level: medium — While the capital raise is positive, the success of the company's drug development pipeline remains a significant factor influencing future performance.
Key Numbers
- $175.1M — Gross Proceeds (From public offering)
- 10.3M — Shares Sold (In public offering)
- $17.00 — Price Per Share (For public offering)
Key Players & Entities
- IDEAYA Biosciences, Inc. (company) — Registrant
- October 17, 2025 (date) — Date of earliest event reported
- 10.3 million (dollar_amount) — Number of shares sold
- $17.00 (dollar_amount) — Price per share
- $175.1 million (dollar_amount) — Gross proceeds
FAQ
What was the total amount of gross proceeds from the public offering?
The total gross proceeds from the public offering were approximately $175.1 million.
How many shares of common stock did IDEAYA Biosciences sell?
IDEAYA Biosciences sold approximately 10.3 million shares of common stock.
At what price per share were the shares sold?
The shares were sold at a price of $17.00 per share.
When did the event reported in this 8-K occur?
The earliest event reported in this 8-K occurred on October 17, 2025.
What is the primary purpose of the capital raised?
The capital raised is intended to provide IDEAYA Biosciences with additional capital to advance its clinical programs and pipeline.
Filing Stats: 1,931 words · 8 min read · ~6 pages · Grade level 15 · Accepted 2025-10-20 16:05:19
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IDYA The Nasdaq
Filing Documents
- d42028d8k.htm (8-K) — 44KB
- 0001193125-25-243558.txt ( ) — 160KB
- idya-20251017.xsd (EX-101.SCH) — 3KB
- idya-20251017_lab.xml (EX-101.LAB) — 18KB
- idya-20251017_pre.xml (EX-101.PRE) — 11KB
- d42028d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements Certain statements contained herein are forward-looking statements, including, but not limited to, statements related to (i) the potential therapeutic benefits of the Company's therapeutics, such as combination therapies and darovasertib (including in combination with crizotinib); (ii) the safety and efficacy profile of darovasertib; (iii) the timing of reporting topline and median PFS data from Phase 2/3 OptimUM-02 trial; (iv) the ongoing Phase 3 registrational trial (OptimUM-10) of darovasertib; and (v) the potential for U.S. accelerated approval in 1L HLA*A2 negative mUM. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including the Company's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing or commercialization of drug products, the outcome of pricing, coverage and reimbursement negotiations with third-party payors for the Company's products, the Company's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. Neither Breakthrough Therapy, Orphan Drug Designation, nor an accelerated approval filing necessarily translates into approval of a drug. The Company undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEAYA BIOSCIENCES, INC. Date: October 20, 2025 By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer